179. Williams syndrome
[
4 clinical trials,
12 drugs（DrugBank:
7 drugs),
8 target genes / 29 target pathways ]
Searched query = "Williams syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-006059-37-ES | 27/05/2009 | 19 March 2012 | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1. MedDRA version: 9.1 Level: LLT Classification code 10049644 Term: Williams syndrome | Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula Pharmaceutical Form: Oral solution INN or Proposed INN: LOSARTAN POTASICO Other descriptive name: LOSARTAN POTASSIUM Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron | Authorised | Female: yes Male: yes | 60 | Spain | ||||
| 2 | EUCTR2006-005745-11-FR | 03/04/2008 | 19 March 2012 | Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé | Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé | Williams syndrome MedDRA version: 9.1 Level: LLT Classification code 10049644 Term: Williams syndrome | Trade Name: LONOTEN Pharmaceutical Form: Tablet INN or Proposed INN: MINOXIDIL CAS Number: 38304915 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Hospices Civils de Lyon | Authorised | Female: yes Male: yes | France | |||||
| 3 | NCT00768820 | May 2001 | 26 August 2019 | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors | Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome | Drug: methylphenidate, fluoxetin, risperidone | The Chaim Sheba Medical Center | Recruiting | N/A | N/A | All | 400 | Phase 4 | Israel | |
| 4 | NCT00013962 | September 1998 | 19 February 2015 | Vitamin D Metabolism and the Williams Syndrome | Vitamin D Metabolism and the Williams Syndrome | Williams Syndrome | Drug: Vitamin D | National Center for Research Resources (NCRR) | Not recruiting | 18 Years | 50 Years | Both | N/A | United States |